UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (7), p.610-621

2020

Volltextzugriff (PDF)

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

International journal of cancer, 2019-09, Vol.145 (5), p.1179-1188

2019

Volltextzugriff (PDF)

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Journal of clinical oncology, 2017-11, Vol.35 (32), p.3638-3646

2017

Volltextzugriff (PDF)

Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy

Scientific reports, 2021-06, Vol.11 (1), p.12105-12105, Article 12105

2021

Volltextzugriff (PDF)

Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer

Oncotarget, 2016-04, Vol.7 (17), p.24677-24687

2016

Volltextzugriff (PDF)

Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP)

Lab on a chip, 2011-03, Vol.11 (6), p.1118-1125

2011

Volltextzugriff (PDF)

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

NPJ breast cancer, 2021-06, Vol.7 (1), p.80-80, Article 80

2021

Volltextzugriff (PDF)

Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib

Breast cancer research and treatment, 2020-12, Vol.184 (3), p.743-753

2020

Volltextzugriff (PDF)

Reply to A. Okeya et al

Journal of clinical oncology, 2024-10, Vol.42 (28), p.3380-3381

2024

Volltextzugriff (PDF)

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2

Cancer science, 2023-01, Vol.114 (1), p.221-226

2023

Volltextzugriff (PDF)

Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation

Experimental & molecular medicine, 2024-04, Vol.56 (4), p.987-1000

2024

Volltextzugriff (PDF)

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer

Journal of experimental & clinical cancer research, 2023-11, Vol.42 (1), p.1-325, Article 325

2023

Volltextzugriff (PDF)

Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older

Breast cancer research and treatment, 2020-02, Vol.179 (3), p.687-697

2020

Volltextzugriff (PDF)

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

Breast cancer research : BCR, 2023-01, Vol.25 (1), p.4-16, Article 4

2023

Volltextzugriff (PDF)

Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts

International journal of molecular sciences, 2022-08, Vol.23 (16), p.9140

2022

Volltextzugriff (PDF)

Investigator initiated clinical trials in Korea; current issues and perspectives focusing in breast cancer trial

Annals of oncology, 2018-10, Vol.29, p.vii4-vii4

Sohn, Joohyuk

2018

Volltextzugriff (PDF)

AOJS-5Investigator initiated clinical trials in Korea; current issues and perspectives focusing in breast cancer trial

Annals of oncology, 2018-10, Vol.29 (suppl_7)

Sohn, Joohyuk

2018

Volltextzugriff (PDF)

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials

Cancer science, 2021-06, Vol.112 (6), p.2381-2392

2021

Volltextzugriff (PDF)

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)

Therapeutic advances in medical oncology, 2021-12, Vol.13, p.17588359211061989-17588359211061989

2021

Volltextzugriff (PDF)

Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer

Breast cancer research and treatment, 2020-08, Vol.183 (1), p.107-116

2020

Volltextzugriff (PDF)

Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer

Cancers, 2022-05, Vol.14 (10), p.2405

2022

Volltextzugriff (PDF)

Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer

Breast cancer research and treatment, 2020-09, Vol.183 (2), p.493-493

2020

Volltextzugriff (PDF)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

Frontiers in oncology, 2021-06, Vol.11, p.689587-689587

2021

Volltextzugriff (PDF)

Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer

iScience, 2024-08, Vol.27 (8), p.110469, Article 110469

2024

Volltextzugriff (PDF)

1 – 25 von 199

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(174)

Publikationsform

Artikel
(199)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(98)
Life Sciences & Biomedicine
(91)
Oncology
(83)
Humans
(67)
Female
(63)
Breast Cancer
(54)
Breast Neoplasms - Drug Therapy
(42)
Adult
(37)
Middle Aged
(37)
Breast Neoplasms - Pathology
(34)
Aged
(27)
Chemotherapy
(27)
Erbb-2 Protein
(27)
Metastasis
(27)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(22)
Patients
(22)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(19)
Cancer Therapies
(19)
Metastases
(19)
Tumors
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy

Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer

Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP)

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib

Reply to A. Okeya et al

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2

Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer

Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts

Investigator initiated clinical trials in Korea; current issues and perspectives focusing in breast cancer trial

AOJS-5Investigator initiated clinical trials in Korea; current issues and perspectives focusing in breast cancer trial

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)

Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer

Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer

Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer

Suchergebnisse filtern